Clinical Trials Browser

Phase 3 × Dermatologic × 30 days × Clear all

NCT05352672 2026-04-22

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Neoplasm Metastasis

NCT06585410 2026-04-22

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Phase 3 Recruiting

Skin Neoplasms

NCT07144345 2026-04-22

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

Phase 3 Recruiting

DermatologicOther neoplasm

Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT07144852 2026-04-22

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Phase 3 Recruiting

DermatologicOther neoplasm

Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT01682083 2026-04-21

COMBI-AD

Phase 3 Completed

870 enrolled 15 charts 1 FDA

Melanoma, Neoplasms

NCT06743126 2026-04-21

SUPRAME

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

NCT06568172 2026-04-20

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Recruiting

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT07530887 2026-04-15

NORMA-2

Phase 3 Recruiting

Melanoma

NCT02821013 2026-04-14

STOP-GAP

Phase 3 Recruiting

Melanoma

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT03271372 2026-04-13

ADAM

Phase 3 Active not recruiting

Carcinoma, Merkel Cell

NCT04099251 2026-04-09

CheckMate76K

Phase 3 Active not recruiting

790 enrolled 18 charts 2 FDA

Melanoma

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05662202 2026-04-03

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Phase 3 Active not recruiting

Keratosis, Actinic

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Phase 3 Recruiting

Melanoma, Skin Neoplasms

NCT06470451 2026-04-03

FLASH2

Phase 3 Recruiting

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT06500455 2026-04-03

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Phase 3 Recruiting

BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 2 FDA

Cutaneous Squamous Cell Carcinoma

NCT05907122 2026-03-27

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Phase 3 Completed

Melanoma

NCT06135415 2026-03-25

TirbAKare

Phase 3 Completed

DermatologicOther neoplasm

Keratosis, Neoplasms, Precancerous Conditions, Keratosis, Actinic